They have rigorously examined serological specimens from a large cohort of patients with various cancer types, and have successfully identified serum NY‐ESO‐1 antibodies (s‐NY‐ESO‐1‐Abs) as a distinctive biomarker for esophageal cancer. This evidence concerns the gene CTAG1B and cancer.